The resurgence of the COVID-19 cases and high inflation has worried investors about the pace of the global economic recovery. In addition, consumer confidence fell to a six-month low in August. However…
Federal Reserve Chair Jerome Powell reiterated that high inflation is ‘temporary.’ The major stock market indexes rallied over the past week on the Fed’s dovish comments related to its tapering activities.
In addition, the economy has witnessed a substantial decline in the unemployment rate recently. Against this backdrop, the prospects for small-cap stocks look promising.
Harmony Biosciences Holdings, Inc. (HRMY – Get Rating), Tupperware Brands Corporation (TUP – Get Rating), and Thryv Holdings, Inc. (THRY – Get Rating) have gained significantly over the past few months and have plenty of upsides left given the favorable backdrop. Wall Street analysts expect these stocks to rally by more than 40% in the near term. So, it could be wise to bet on them now.
Commercial-stage pharmaceutical company HRMY develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX, is a medication used to treat excessive daytime sleepiness in adult patients with narcolepsy. It has a market capitalization of $2.06 billion.
On August 10, 2021, HRMY and Blackstone (BX) announced entering into a strategic financing collaboration. John C. Jacobs, HRMY’s President, and CEO said, “This financing provides us with further flexibility to grow our business by providing us with access to capital to expand our portfolio of assets in rare, neurological diseases while also reducing our annual interest expense.”
HRMY’s net product revenue increased 94.2% year-over-year to $73.82 million for the second quarter ended June 30, 2021. Its adjusted EBITDA grew 214.6% year-over-year to $28.04 million, while its adjusted net income increased 221.3% year-over-year to $31.87 million. In addition, its adjusted EPS came in at $0.54 compared to a loss per share of $0.07 in the prior year period.
HRMY’s EPS is expected to increase 385.7% year-over-year to $1.02 in fiscal 2021. The company’s revenue is expected to increase 101.9% year-over-year to $80.90 million for the quarter ending September 30, 2021.
Over the past year, the stock has gained 33% to close Friday’s trading session at $36.15. Wall Street analysts expect the stock to hit $56.50 in the near term, which indicates a potential upside of 56.3%.
HRMY’s POWR Ratings reflect this promising outlook. The company has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
The stock has an A grade for Growth and Sentiment, and a B grade for Value and Quality. Within the Medical – Pharmaceuticals industry, it is ranked #12 of 217 stocks. Click here to see the additional POWR Ratings for HRMY (Stability and Momentum).
TUP operates as a consumer products company and has a market capitalization of $1.18 billion. The company manufactures, markets, and sells design-centric preparation, storage, and serving solutions for the kitchen and home, as well as an array of products for on-the-go consumers under the Tupperware brand name.
On June 22, 2021, TUP announced…
Continue reading at STOCKNEWS.com